Recent Updates
Recently added Catalysts
QTRX Positive Sentiment

Quanterix Expands Access to Blood-Based Alzheimer's Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory

Key Takeaway: Quanterix Corporation has formed an exclusive distribution agreement with Sherman Abrams Laboratory to provide its LucentAD Complete blood tests in New Jersey. This test, utilizing the SIMOA platform, is among the first to screen for various biomarkers linked to Alzheimer's disease, enhancing diagnostic capabilities in the region.

Market Sentiment Analysis

POSITIVE FACTORS

  • Exclusive partnership with Sherman Abrams Laboratory
  • Expansion of blood-based Alzheimer's testing in New Jersey
  • LucentAD Complete tests for multiple biomarkers

Full Press Release Details

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX) today announced an exclusive distribution agreement with Sherman Abrams Laboratory, a Brooklyn-based clinical and anatomic pathology lab, to bring its LucentAD® Complete blood tests to patients across New Jersey and the surrounding area. LucentAD Complete from Quanterix is powered by the SIMOA® platform and is one of the first blood-based tests to screen for multiple biomarkers associated with Alzheimer's disease, helping p

Frequently Asked Questions

What is the LucentAD Complete test?

It is a blood test that screens for multiple biomarkers associated with Alzheimer's.

Who is Quanterix partnering with?

Quanterix has partnered with Sherman Abrams Laboratory for distribution.

Where will the Alzheimer's testing be available?

The testing will be available across New Jersey and surrounding areas.

What technology powers the LucentAD Complete test?

The test is powered by the SIMOA platform.

Last updated: Nov 16, 2026